We use cookies in order to analyze traffic of this website. Your further use of this website will be considered consent. For more information visit our Cookie Policy.

SEC Filings

Form 424B4
AC IMMUNE SA filed this Form 424B4 on 09/23/2016
Document Outline
Entire Document (3946 KB)
Subdocument 1 - 424B4 - 424B4
Page 1 - Filed Pursuant to Rule 424(b)(4)
Page 2 - TABLE OF CONTENTS
Page 3 - DEALER PROSPECTUS DELIVERY OBLIGATION
Page 4 - PROSPECTUS SUMMARY
Page 5 - N/A
Page 6 - N/A
Page 7 - Our Proprietary Platform Technologies
Page 8 - Risks Associated with Our Business
Page 9 - Implications of Being an Emerging Growth Company
Page 10 - Anti-Tau Antibody Phase 1 Milestone Payment
Page 11 - THE OFFERING
Page 12 - N/A
Page 13 - SUMMARY HISTORICAL AND OTHER FINANCIAL INFORMATION
Page 14 - N/A
Page 15 - RISK FACTORS
Page 16 - Additional competitors could enter the market with generic versions of our products, which may resul
Page 17 - One of our collaboration partners is evaluating a product candidate in the same indication as our le
Page 18 - The successful commercialization of our product candidates will depend in part on the extent to whic
Page 19 - We depend on enrollment of patients in our clinical studies for our product candidates. If we are un
Page 20 - We operate in highly competitive and rapidly changing industries, which may result in others discove
Page 21 - We may not be successful in our efforts to use and expand our Morphomer and SupraAntigen proprietary
Page 22 - Our business is subject to economic, political, regulatory and other risks associated with internati
Page 23 - Our future growth and ability to compete depends on retaining our key personnel and recruiting addit
Page 24 - We may seek to obtain orphan drug designation for certain of our product candidates. Orphan drug des
Page 25 - Due to our limited resources and access to capital, we must prioritize development of certain produc
Page 26 - Risks Related to Our Relationships with Third Parties
Page 27 - We rely on third parties to conduct our nonclinical and clinical studies and perform other tasks for
Page 28 - We currently rely on third-party suppliers and other third parties for production of our product can
Page 29 - Our collaboration arrangements with our strategic partners may make us an attractive target for pote
Page 30 - We or our licensing or collaboration partners may become subject to intellectual property-related li
Page 31 - If we or our licensing or collaboration partners are unable to obtain and maintain effective patent
Page 32 - We may be subject to claims challenging the inventorship of our patents and other intellectual prope
Page 33 - Obtaining and maintaining our patent protection depends on compliance with various procedural, docum
Page 34 - The patent protection and patent prosecution for some of our product candidates is dependent on thir
Page 35 - We may not be successful in obtaining or maintaining necessary rights to our product candidates thro
Page 36 - inter partes
Page 37 - We may be subject to claims that our employees, consultants, or independent contractors have wrongfu
Page 38 - Risks Related to Our Financial Condition and Capital Requirements
Page 39 - Even if this offering is successful, we expect that we will need substantial additional funding befo
Page 40 - Raising additional capital may cause dilution to our shareholders, restrict our operations or requir
Page 41 - Exchange rate fluctuations or abandonment of the euro currency may materially affect our results of
Page 42 - Clinical drug development involves a lengthy and expensive process with uncertain timelines and unce
Page 43 - Even if we obtain and maintain approval for our drug candidates from one jurisdiction, we may never
Page 44 - Even if our product candidates obtain regulatory approval, we will be subject to ongoing obligations
Page 45 - Enacted and future legislation may increase the difficulty and cost for us to obtain marketing appro
Page 46 - We could be subject to liabilities under environmental, health and safety laws or regulations, or fi
Page 47 - Our relationships with customers and payors will be subject to applicable anti-kickback, fraud and a
Page 48 - Risks from the improper conduct of employees, agents, contractors, or collaborators could adversely
Page 49 - Risks Related to this Offering and our Common Shares
Page 50 - Future sales, or the possibility of future sales, of a substantial number of our common shares could
Page 51 - We have broad discretion in the use of the net proceeds from this offering and may not use them effe
Page 52 - Our common shares are issued under the laws of Switzerland, which may not protect investors in a sim
Page 53 - apports de capital
Page 54 - Our status as a Swiss corporation means that our shareholders enjoy certain rights that may limit ou
Page 55 - As a foreign private issuer and as permitted by the listing requirements of NASDAQ, we will rely on
Page 56 - We are an emerging growth company, and we cannot be certain if the reduced reporting requirements ap
Page 57 - If in the future we fail to maintain an effective system of internal control over financial reportin
Page 58 - If securities or industry analysts do not publish research, or publish inaccurate or unfavorable res
Page 59 - CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS
Page 60 - N/A
Page 61 - MARKET AND INDUSTRY DATA
Page 62 - USE OF PROCEEDS
Page 63 - N/A
Page 64 - DIVIDEND POLICY
Page 65 - CAPITALIZATION
Page 66 - N/A
Page 67 - DILUTION
Page 68 - N/A
Page 69 - EXCHANGE RATES
Page 70 - SELECTED FINANCIAL AND OTHER INFORMATION
Page 71 - Balance Sheets
Page 72 - MANAGEMENT S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
Page 73 - Strategic Collaborations and Licensing Agreements
Page 74 - Anti-Tau Antibodies Collaboration with Genentech
Page 75 - Financial Operations Overview
Page 76 - Detailed Research and Development Expenditures by Major Development Program
Page 77 - General and Administrative Expenses
Page 78 - Results of Operations
Page 79 - General and Administrative Expenses
Page 80 - Comparison of the Years Ended December 31, 2015 and 2014
Page 81 - General and Administrative Expenses
Page 82 - Cash Flows
Page 83 - Financing activities
Page 84 - Internal Control over Financial Reporting
Page 85 - Critical Accounting Policies and Significant Judgments and Estimates
Page 86 - Share-Based Compensation
Page 87 - Amendment of 2015 Option Plan
Page 88 - Contractual Obligations and Other Commitments
Page 89 - BUSINESS
Page 90 - N/A
Page 91 - N/A
Page 92 - N/A
Page 93 - Our Strategy
Page 94 - N/A
Page 95 - Our Approach to Treating Diseases Related to Protein Misfolding
Page 96 - Benefits of our approach
Page 97 - Opportunity for AC Immune in Neurodegenerative Diseases
Page 98 - Our Proprietary Technology Platforms
Page 99 - SupraAntigen Platform: Active Immunization
Page 100 - SupraAntigen Platform: Passive Immunization
Page 101 - Our AD Programs
Page 102 - N/A
Page 103 - N/A
Page 104 - Phase 2 Studies
Page 105 - ABBY Study Disposition
Page 106 - ABBY Study Results
Page 107 - ABBY High Dose Arm: Change in DSST
Page 108 - N/A
Page 109 - N/A
Page 110 - BLAZE Study Design
Page 111 - BLAZE Study Results
Page 112 - BLAZE High Dose Arm: Crenezumab Increases CSF Total Abeta Relative to Placebo
Page 113 - Safety Data from ABBY and BLAZE Studies
Page 114 - Phase 2 AD Prevention Study
Page 115 - Pre-clinical Study
Page 116 - ACI-35
Page 117 - Phase 1b Study
Page 118 - Pre-clinical and Discovery Stage Therapeutic Programs
Page 119 - N/A
Page 120 - License Agreements and Collaborations
Page 121 - Anti-tau Antibody Collaboration Agreement of 2012
Page 122 - Janssen Pharmaceuticals
Page 123 - Piramal Imaging
Page 124 - National Institutes of Health/Banner Alzheimer s Institute
Page 125 - N/A
Page 126 - Commercialization Strategy
Page 127 - ACI-24
Page 128 - Collaboration Partners and Contract Manufacturing Organizations
Page 129 - Interaction with collaboration partners and contract manufacturing organizations
Page 130 - N/A
Page 131 - N/A
Page 132 - N/A
Page 133 - Special Protocol Assessment
Page 134 - Orphan Drug Designation
Page 135 - Patent Term Restoration and Marketing Exclusivity
Page 136 - Non-U.S. Regulation
Page 137 - Regulation in the European Union
Page 138 - N/A
Page 139 - Orphan Drug Regulation
Page 140 - Manufacturing and Manufacturers License
Page 141 - Price and Reimbursement
Page 142 - N/A
Page 143 - Pharmaceutical Coverage, Pricing and Reimbursement
Page 144 - Healthcare Reform
Page 145 - Physician Payment Sunshine Act
Page 146 - Legal Proceedings
Page 147 - MANAGEMENT
Page 148 - George Pavey, CFA, Chief Financial Officer
Page 149 - Julian Gray, M.D., Ph.D., Clinical Advisor:
Page 150 - Board Composition and Election of Directors After This Offering
Page 151 - Compensation, Nomination and Governance Committee
Page 152 - Code of Business Conduct and Ethics
Page 153 - Plan Administration
Page 154 - PRINCIPAL SHAREHOLDERS
Page 155 - N/A
Page 156 - RELATED PARTY TRANSACTIONS
Page 157 - Registration Rights Agreement
Page 158 - Related Person Transaction Policy
Page 159 - DESCRIPTION OF SHARE CAPITAL AND ARTICLES OF ASSOCIATION
Page 160 - Pre-Emptive Rights
Page 161 - Our Conditional Share Capital
Page 162 - Voting and Quorum Requirements
Page 163 - Notice
Page 164 - Voting Rights
Page 165 - Transfer of Shares
Page 166 - Board of Directors
Page 167 - Indemnification of Executive Management and Directors
Page 168 - N/A
Page 169 - Borrowing Powers
Page 170 - COMPARISON OF SWISS LAW AND DELAWARE LAW
Page 171 - N/A
Page 172 - N/A
Page 173 - N/A
Page 174 - N/A
Page 175 - N/A
Page 176 - N/A
Page 177 - N/A
Page 178 - COMMON SHARES ELIGIBLE FOR FUTURE SALE
Page 179 - Equity Incentive Plan
Page 180 - TAXATION
Page 181 - Domestic Commercial Shareholders
Page 182 - Swiss Federal Stamp Taxes
Page 183 - Taxation of Distributions
Page 184 - Sale or Other Disposition of Common Shares
Page 185 - Information Reporting and Backup Withholding
Page 186 - Information With Respect to Foreign Financial Assets
Page 187 - UNDERWRITING
Page 188 - N/A
Page 189 - provided
Page 190 - NASDAQ
Page 191 - Notice to Investors in the European Economic Area
Page 192 - Notice to Prospective Investors in the Dubai International Financial Centre
Page 193 - Notice to Prospective Investors in Japan
Page 194 - Representations of Canadian Purchasers
Page 195 - N/A
Page 196 - EXPENSES OF THE OFFERING
Page 197 - LEGAL MATTERS
Page 198 - ENFORCEMENT OF JUDGMENTS
Page 199 - WHERE YOU CAN FIND MORE INFORMATION
Page 200 - INDEX TO FINANCIAL STATEMENTS
Page 201 - Unaudited interim condensed financial statements
Page 202 - Unaudited interim condensed financial statements
Page 203 - Unaudited interim condensed financial statements
Page 204 - Unaudited interim condensed financial statements
Page 205 - Notes to the interim condensed financial statements
Page 206 - Notes to the interim condensed financial statements
Page 207 - Notes to the interim condensed financial statements
Page 208 - Notes to the interim condensed financial statements
Page 209 - Notes to the interim condensed financial statements
Page 210 - Notes to the interim condensed financial statements
Page 211 - N/A
Page 212 - Financial Statements (IFRS)
Page 213 - Financial Statements (IFRS)
Page 214 - Financial Statements (IFRS)
Page 215 - Financial Statements (IFRS)
Page 216 - Financial Statements (IFRS)
Page 217 - Notes to the Financial Statements (IFRS)
Page 218 - Notes to the Financial Statements (IFRS)
Page 219 - Notes to the Financial Statements (IFRS)
Page 220 - Notes to the Financial Statements (IFRS)
Page 221 - Notes to the Financial Statements (IFRS)
Page 222 - Notes to the Financial Statements (IFRS)
Page 223 - Notes to the Financial Statements (IFRS)
Page 224 - Notes to the Financial Statements (IFRS)
Page 225 - Notes to the Financial Statements (IFRS)
Page 226 - Notes to the Financial Statements (IFRS)
Page 227 - Notes to the Financial Statements (IFRS)
Page 228 - Notes to the Financial Statements (IFRS)
Page 229 - Notes to the Financial Statements (IFRS)
Page 230 - Notes to the Financial Statements (IFRS)
Page 231 - Notes to the Financial Statements (IFRS)
Page 232 - Notes to the Financial Statements (IFRS)
Page 233 - Notes to the Financial Statements (IFRS)
Page 234 - Notes to the Financial Statements (IFRS)
Page 235 - Notes to the Financial Statements (IFRS)
Page 236 - Notes to the Financial Statements (IFRS)
Page 237 - Notes to the Financial Statements (IFRS)
Page 238 - Notes to the Financial Statements (IFRS)
Page 239 - N/A